Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
18F-metaFluorobenzylguanidine · 1 trial · 3 indications
Obtain computer quantification of global and/or regional differences in myocardial sympathetic innervation (based on 18F-mFBG uptake) between subjects who have and have not experienced an appropriate ICD activation within the previous 12 months
| Arm | Type | Description |
|---|---|---|
| Ischemic cardiomyopathy with ICD discharge | ACTIVE_COMPARATOR | 82Rb and 18F-mFBG will be administered to intraveously to 10 heart failure patients with ischemic cardiomyopathy and an ICD discharge within the past 12 months |
| Ischemic cardiomyopathy without ICD discharge | ACTIVE_COMPARATOR | 82Rb and 18F-mFBG will be administered intravenously to 10 heart failure patients with ischemic cardiomyopathy and no ICD discharge within the past 12 months |
| Name | Type | Description |
|---|---|---|
| 18F-metaFluorobenzylguanidine | DRUG | PET Radiopharmaceutical to assess myocardial sympathetic innervation |
| Rubidium-82 | DRUG | PET Radiopharmaceutical to assess myocardial perfusion |
Inclusion Criteria: * Stable heart failure from ischemic cardiomyopathy, LVEF \< or = 35%, ICD implantation for at least 12 months Exclusion Criteria: * Unstable coronary artery disease, no ICD implantation
Top 20 of 31 competitors